Entest BioMedical Inc. (OTCBB: ENTB) announced today that Chairman & CEO David Koos, along with Lead Inventor Dr. Steven Josephs, provided clarification on the Company's new patent application for use of chemokines in its stem cell / photoceutical therapy for treatment of Chronic Obstructive Pulmonary Disease (COPD) during the Company's weekly blogcast held March 23, 2010.
Dr. Josephs noted, "Chemokines are naturally produced in the body during times of injury and are believed to be an essential part of the healing process. These chemokines cause stem cells to 'home' to injured areas. It is our belief the addition of chemokines to our COPD treatment model will aid in focusing stem cells towards damaged lung tissue painted by our photoceutical device."
Entest's Chairman & CEO David Koos said, "In its simplest form, our COPD treatment model consists of three components: an alarm clock, a bus for transportation and a GPS navigational system. An FDA approved stem cell mobilizer acts as an alarm clock activating the stem cells. Chemokines serve as the 'bus' transporting the stem cells to a location in the body. The laser serves as a GPS system navigating the bus to the destination -- damaged lung tissue."
The entire blogcast has been archived on the Company's blog site: www.entestbioblog.com.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation). ENT-576™ is a proprietary laser device currently under development by Entest. The Company has filed 4 patent applications relating to the treatment of COPD. Entest BioMedical Inc. is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB: BMSN). Recently Entest published in the peer reviewed literature its platform technology, which is available at http://www.translational-medicine.com/content/pdf/1479-5876-7-106.pdf.
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact: David R. Koos, Chairman & CEO Entest BioMedical Inc. 619.702.1404 Direct 619.330.2328 Fax www.entestbio.com firstname.lastname@example.org